Susan Stanforth
Nurse Practitioner · Poughkeepsie, NYNPI 1861972689
Payments from drug & device makers
Across 250 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$892
- Novartis$711
- AstraZeneca$500
- E.r. Squibb & Sons, L.L.C.$482
- Lilly USA, LLC$384
- Pfizer$280
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,10695%
- Education$2705%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 31 | $892 |
| Novartis | 37 | $711 |
| AstraZeneca(2 entities) | 26 | $500 |
| E.r. Squibb & Sons, L.L.C. | 26 | $482 |
| Lilly USA, LLC | 10 | $384 |
| Pfizer | 15 | $280 |
| Amgen | 10 | $211 |
| Bayer | 9 | $181 |
| Ipsen Biopharmaceuticals, Inc | 10 | $172 |
| Merck | 9 | $171 |
| Gilead(2 entities) | 5 | $142 |
| Daiichi Sankyo Inc. | 5 | $126 |
| Seagen Inc. | 6 | $120 |
| Incyte Corporation | 6 | $106 |
| AbbVie | 5 | $97 |
| Puma Biotechnology, Inc. | 5 | $87 |
| Bristol Myers Squibb | 5 | $76 |
| Beigene USA, Inc. | 2 | $55 |
| Boston Scientific | 2 | $52 |
| Adaptive Biotechnologies Corporation | 3 | $51 |
| AVEO Pharmaceuticals, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $42 |
| Eisai Inc. | 2 | $41 |
| Genentech USA, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $33 |
| Sanofi | 1 | $32 |
| Taiho Oncology, Inc. | 2 | $31 |
| ADC Therapeutics America, Inc. | 1 | $27 |
| GSK | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| TG Therapeutics, Inc. | 1 | $13 |
| Menarini Silicon Biosystems, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,376 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 39 | $723,128 |
| PomalystPomalidomide | 22 | $486,015 |
| FotivdaTivozanib Hcl | 13 | $403,005 |
| IdhifaEnasidenib Mesylate | 11 | $363,491 |
| RevlimidLenalidomide | 20 | $362,700 |
| LynparzaOlaparib | 19 | $318,180 |
| AranespDarbepoetin Alfa In Polysorbat | 75 | $213,846 |
| ImbruvicaIbrutinib | 15 | $197,967 |
| IbrancePalbociclib | 13 | $196,969 |
| Lenalidomide | 14 | $191,506 |
| NinlaroIxazomib Citrate | 14 | $174,686 |
| XareltoRivaroxaban | 120 | $122,519 |
| EliquisApixaban | 131 | $121,410 |
| VenclextaVenetoclax | 17 | $115,504 |
| CalquenceAcalabrutinib Maleate | 12 | $107,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbIdhifa, Revlimid | $76 | $726,19131 claims |
| Incyte CorporationJakafi | $106 | $723,12839 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $482 | $486,01522 claims |
| AstraZenecaLynparza, Calquence | $500 | $425,30031 claims |
| PfizerIbrance, Eliquis, Nivestym | $280 | $346,373163 claims |
| AmgenAranesp | $211 | $213,84675 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $18 | $174,68614 claims |
| Johnson & JohnsonXarelto | $892 | $122,519120 claims |
| AbbVieVenclexta | $97 | $115,50417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Poughkeepsie
- Hani KhalilPoughkeepsie$18K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.